Table 1.
Baseline demographic and clinical characteristics.
| Total patient number | N = 63 |
|---|---|
| Age | |
| Median year (range) | 67 (25–85) |
| Gender, n (%) | |
| Male | 47 (74.6) |
| Female | 16 (25.4) |
| Nephrectomy, n (%) | |
| Yes | 50 (79.4) |
| Histology, n (%) | |
| Clear cell | 58 (92.1) |
| With spindle component | 13 (20.6) |
| Papillary | 4 (6.3) |
| Chromphobe | 2 (3.2) |
| Xp11.2 translocation | 2 (3.2) |
| Clinical stage at the time of diagnosis with RCC, n (%) | |
| 1 | 17 (27.0) |
| 2 | 6 (9.5) |
| 3 | 8 (12.7) |
| 4 | 32 (50.8) |
| IMDC risk classification, n (%) | |
| Favorable | 7 (11.1) |
| Intermediate | 33 (52.4) |
| Poor | 23 (36.5) |
| Metastatic site, n (%) | |
| 1 | 18 (28.6) |
| 2 | 19 (30.2) |
| 3 | 9 (14.3) |
| 4 ≤ | 17 (27.0) |
| ECOG PS, n (%) | |
| 0 | 39 (61.9) |
| 1 | 13 (20.6) |
| 2 ≤ | 11 (17.5) |
| Site of metastases, n (%) | |
| Lung | 49 (77.8) |
| Lymph node | 37 (58.7) |
| Bone | 21 (33.3) |
| Liver | 12 (19.0) |
| Adrenal gland | 6 (9.5) |
| Brain | 5 (7.9) |
| Opposite kidney | 5 (7.9) |
| Others | 11 (17.5) |
| Time from diagnosis to systemic therapy, n (%) | |
| < 1 year | 31 (49.2) |
| Neutrophil–lymphocyte ration, n (%) | |
| > 2.9 | 31 (49.2) |
| Hemoglobin, n (%) | |
| < Lower limit of normal | 49 (77.8) |
| Platelet count, n (%) | |
| > 34.8 × 104/μL | 11 (17.5) |
| Albumin, n (%) | |
| < 3.7 g/dL | 30 (47.6) |
| Corrected carcium, n (%) | |
| > 10 mg/dL | 4 (6.3) |
| LDH, n (%) | |
| > 1.5 × upper limit of normal | 5 (7.9) |
| CRP, n (%) | |
| > 0.5 mg/dL | 32 (50.8) |
IMDC International Metastatic Renal Cell Carcinoma Database Consortium, ECOG Eastern Cooperative Oncology, PS performa status, LDH lactate dehydrogenase, CRP C-reactive protein.